Which newer treatment option inhibits both Anti-VEGF A and Ang-2 and is thought to work longer?

The correct answer is Faricimab, which is a newer treatment option designed to target both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). This dual inhibition is significant because it aims to address multiple pathways involved in the development of neovascular age-related macular degeneration (AMD) and other causes of choroidal neovascularization (CNV).

Faricimab's mechanism of action allows it to not only reduce the vascular permeability and neovascularization driven by VEGF-A but also to modulate the angiopoietin pathway, which plays a role in vascular stability and inflammation. This dual action is thought to contribute to a longer-lasting therapeutic effect compared to treatments that solely focus on VEGF-A, potentially decreasing the frequency of required injections.

The efficacy of Faricimab supports its use in clinical settings, especially for patients who may benefit from fewer treatment visits while still achieving effective control of their retinal conditions.